News Regeneron swoops on genetic testing firm 23andMe DNA testing company 23andMe looks destined to be taken over by a pharma company, as Regeneron agrees a $256 million acquisition deal.
News BioMarin starts rebuilding after its downsizing spree BioMarin has made its first M&A play under James Sabry, buying Inozyme to flesh out its enzyme replacement therapies (ERTs) for rare diseases.
News Datavant, Aetion merger creates real-world data force Datavant and Aetion merger promises "faster, more actionable" real-world data insights across pharma's clinical and commercial lifecycle.
News GSK pays $1.2bn for liver drug as it culls TIGIT programme GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH.
News Shionogi aims to buy tobacco giant's pharma unit for $1bn Shionogi has reached a $1.04bn agreement to buy Torii, the pharma subsidiary of Japan Tobacco, as it tries to meet an ambitious sales target.
News Novartis grabs kidney drug developer Regulus in $1.7bn deal Novartis has grown in renal diseases once again with a $1.7bn deal to buy Regulus and its autosomal dominant polycystic kidney disease (ADPKD) drug.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
